The Week Ahead: Hom...
Health Care: Drugs
Neuralstem Inc. (CUR: AMEX)
$1.49 0.04 | 2.76%
05/17/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 1.49 |
| 52 Week High | 1.96 |
| 52 Week Low | 0.42 |
| Avg. Daily Vol. (Mil) | 0.41 |
| Beta (3 year) | 1.29 |
| Share Related Items | |
| Mkt Cap (Mil) | 102.51 |
| Shares Out (Mil) | 68.80 |
| Float (Mil) | 64.98 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 4.80 |
| Current Ratio | 5.10 |
| LT Debt/ Equity | 1.24 |
| Total Debt / Equity | 1.33 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 289.61 |
| Price/Book | 18.00 |
| Price/Cash Flow | -7.60 |
| Per Share Data | |
| Earnings | -0.16 |
| Sales | 0.01 |
| Book Value | 0.08 |
| Cash Flow | -0.20 |
| Business Summary | |
|---|---|
| Neuralstem Inc is an biotechnology company, which is engaged in the development and commercialization of treatments for central nervous system disease based on transplanting human neural stem cells and the use of small molecule drugs. | |
| General Information | |
| 9700 Great Seneca Highway
Rockville, MD 20850 |
|
| www.neuralstem.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 16 | |
| CEO: I. Richard Garr | |
| Short Interest | |
| Current Month (Mil) | 3.36 |
| Previous Month (Mil) | 3.36 |
| Short Interest Ratio (Days) | 10.50 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -89.00 |
| Return on Investments | -107.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with CUR
- Portfolio NameUser Type
- Userdennis diamonds
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- Usermine
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- UserBio
- Userjustin
- ContributorBreakout Stocks Of The Week...
Latest CUR Headlines from TheStreet
- 4 Biotech Stocks Under $10 Moving Higher 11.27.12 | 02:11 pm
- 4 Biotech Stocks Under $10 Moving Higher 10.05.12 | 08:10 am
- Stocks Close Week Higher on QE3 Confidence 09.14.12 | 05:09 pm
- 5 Stocks Under $10 Setting Up to Break Out 09.13.12 | 12:09 pm
- 5 Stocks Poised for Big Breakouts 08.31.12 | 01:08 pm
- 9 Biotech Penny Stocks to Buy 08.31.10 | 10:08 am
- Interstate Hotel, Neuralstem: Midday Volume Plays 12.18.09 | 01:12 pm
- Four Must-See Charts: Stem Cell Stocks 07.02.09 | 03:07 pm
- Stem cell firms jump on Obama policy plans 03.06.09 | 06:03 pm
- Wednesday's Health Winners & Losers 09.19.07 | 04:09 pm
Press Releases for CUR
- Neuralstem CEO, Richard Garr, To Present At Annual World Stem Cells And Regenerative Medicine Congress In London - PR Newswire 05.16.13 | 09:05 am
- DiagnoCure Announces Presentation On Previstage GCC At The 2013 ASCO Annual Meeting - PR Newswire 05.16.13 | 07:05 am
- Neuralstem Principal Investigator, Dr. Eva Feldman, Presents Phase I ALS Trial Data At The Romanian Neurological Society Congress - PR Newswire 05.13.13 | 09:05 am
- Neuralstem ALS Trial Investigator And Patient On Sirius XM - PR Newswire 05.08.13 | 09:05 am
- Neuralstem ALS Trial Data Presented At The American Association Of Neurological Surgeons Annual Meeting - PR Newswire 04.29.13 | 11:04 am
- DiagnoCure's Update Presentation During The Annual And Special Meeting Of Shareholders - PR Newswire 04.29.13 | 07:04 am
- Neuralstem And The National Football League Alumni Association Announce Initiative On Brain Injury Treatment - PR Newswire 04.24.13 | 09:04 am
- FDA Approves Neuralstem To Treat Final Cohort In NSI-189 Phase Ib Trial In Major Depressive Disorder - PR Newswire 04.22.13 | 09:04 am
- Neuralstem CEO, Richard Garr, To Participate In Traumatic Brain Injury Panel At BIO International Convention - PR Newswire 04.18.13 | 09:04 am
- Neuralstem Receives FDA Approval To Commence Phase II Stem Cell Trial In Amytrophic Lateral Sclerosis - PR Newswire 04.17.13 | 08:04 am
Partner Headlines for CUR
- Brainstorm's Breakthrough ALS Clinical Data Shows The Promise In Stem Cell Therapy - Seeking Alpha 03.28.13 | 09:03 am
- 3 Regenerative Medicine Companies That Could Deliver In 2013 - Seeking Alpha 01.22.13 | 09:01 am
- Biotech Under The Electron Microscope: What's In The Pipeline And Lessons To Be Learned - Seeking Alpha 12.16.12 | 08:12 am
- Neuralstem Swinging For The ALS Fences - Seeking Alpha 10.29.12 | 09:10 am
- 4 Biotechs That Just Got Mauled By Bears - Seeking Alpha 10.10.12 | 09:10 am
- Morning Market Movers - Benzinga 10.04.12 | 09:10 am
- Dr. Eva Feldman, Principal Investigator, To Update Interim Data On Neuralstem ALS Trial - Benzinga 10.04.12 | 09:10 am
- Neuralstem Grants First Licenses for CNS Therapy Surgical Devices - Benzinga 09.06.12 | 09:09 am
- ALS Patient's Survival is "One of the Most Powerful Stories" Ever Reported - Benzinga 08.27.12 | 01:08 pm
- End-of-Day Market Summary for November 23, 2011 - Benzinga 11.23.11 | 04:11 pm
